Top 25 Countries Allergy Immunotherapies Market 2019-2025 & Competitive Intelligence of Top 10 Companies
Allergy
immunotherapy, conjointly stated as desensitization or hypo-sensitization, is a medical
treatment targeted for various sorts of allergies. Rise in prevalence of
allergy and pharmacotherapy alone is insufficient to regulate the sickness. The
allergy immunotherapeutic treatment helps increase immunological tolerance and
alters the sickness course. The hypo-sensitization therapy provides long-term impact
that extends past the conclusion of treatment. This therapy improves the
quality of life of allergic patients.
Allergy Immunotherapy Market was valued at US$ 1.54 Bn in 2018 and expected to grow at 10.9 % Compound
Annual Growth Rate (CAGR) over 2019 to 2025. The increasing prevalence of varied sorts of allergies across
the world is driving the allergy immunotherapies market. The growing incidence
of allergy is generated by factors like increasing pollution and augmented
consumption of tobacco product like cigarettes, that is probably going to boost
the worldwide allergy immunotherapy market.
The Unknown
pathogenesis of varied allergies is that the major challenge faced by the
worldwide allergy immunotherapies market. The unclear explanation for allergy
ends up in physicians misdiagnosing the allergen, and as a result, the
treatment prescribed is not as effective because it ought to be, and it usually
ends up in adverse events.
The following companies are the key players in Allergy Immunotherapy
Market: There are plenty of large and small market players which operate in
this market all over the globe.
·
ALK Abello A/S (Denmark),
·
DBV Technologies (France),
·
Stallergenes Greer (UK),
·
HAL Allergy Group (Netherlands),
·
Allergy Therapeutics (UK),
·
Merck KGaA (Allergopharma) (Germany), and
·
Circassia (UK) among others.
Geographically, the allergy immunotherapy
market has been categorised into 5 regions: North America, Europe, Asia
Pacific, Latin America, and the Middle East. Europe accounted for the biggest share of the world allergy
immunotherapy market in 2018, followed by North America. Europe accounts
for an oversized share of the market because of high awareness, increase in
funding for research and grants, favourable medical reimbursement policies, the
rise in allergic population, and promising clinical pipeline product. The
region may be an extremely engaging market and is anticipated to expand at a
major CAGR throughout the forecast period. The allergy immunotherapy market in
the Asia Pacific is anticipated to expand at a moderate rate of growth. Majority
of the market share of allergy immunotherapy is captured by Japan and China in
the Asia-Pacific region, because of the presence of a big allergic population
in these countries.
Segments
for Global Allergy Immunotherapy Market
By allergy type, the global
allergy immunotherapy market has been segmented into
·
allergic rhinitis
·
allergic asthma
·
peanut allergy
·
cat allergy
·
other allergies.
The allergic rhinitis segment currently
accounts for a dominant share of the market. Meanwhile, the peanut allergy
segment is estimated to register a CAGR of xx %.
By
treatment, the allergy immunotherapy market is segmented into
·
Subcutaneous Immunotherapy (SCIT)
·
sublingual immunotherapy
·
Specific Immunotherapy (SIT).
The Subcutaneous Immunotherapy
(SCIT) segment holds the largest share of the market and is projected to reach
a valuation of USD xx Bn by 2025.
Comments
Post a Comment